INVESTOR & PRIVAGE EQUITY DUE DILIGENCE
Investor & Private Equity Due Diligence
De-Risking Investments. Enabling Better Decisions.
Investing in pharmaceutical, biotechnology, and medical technology companies requires navigating scientific complexity, regulatory uncertainty, and operational risk. Traditional financial diligence alone is insufficient—successful investment decisions depend on deep technical, clinical, and regulatory insight.
Our advisory platform provides comprehensive, multidisciplinary due diligence to help investors evaluate opportunities, mitigate risk, and maximize returns.
Our Approach
Scientific Rigor. Commercial Perspective. Investor Focus.
We deliver independent, expert-driven diligence across all critical dimensions of a life sciences investment:
- Scientific and clinical viability
- Regulatory pathway and risk
- Manufacturing feasibility and scalability
- Commercial potential and market dynamics
- Operational execution capability
Our work is grounded in real-world operating experience, enabling us to move beyond theoretical analysis to practical, decision-ready insights.
Core Due Diligence Capabilities
1. Scientific & Technical Evaluation
What We Assess
- Target biology and mechanism of action
- Strength and reproducibility of preclinical data
- Differentiation vs. competitive landscape
- Platform technology robustness
Key Questions We Answer
- Is the science credible and validated?
- Does the mechanism support clinical success?
- Is the technology differentiated or commoditized?
Value
- Identifies fundamental scientific risks early
- Prevents investment in non-viable technologies
- Provides confidence in core innovation
2. Preclinical & Clinical Assessment
What We Assess
- Quality and completeness of preclinical data
- IND readiness and study design
- Clinical trial design and endpoints
- Probability of technical and regulatory success (PTRS)
Key Questions
- Is the development plan robust and executable?
- Are clinical endpoints appropriate and achievable?
- What are the key risks to trial success?
Value
- Clarifies likelihood of clinical success
- Identifies gaps in development strategy
- Supports go/no-go investment decisions
3. Clinical Pharmacology & Data Analysis
What We Assess
- PK/PD and exposure-response relationships
- Dose selection and optimization strategy
- Modeling and simulation (MIDD) approach
- Clinical data interpretation
Key Questions
- Is the dosing strategy scientifically sound?
- Does the data support efficacy claims?
- Are there hidden risks in variability or exposure?
Value
- Improves confidence in clinical data
- Identifies optimization opportunities
- Reduces late-stage surprises
4. Regulatory Strategy & Risk
What We Assess
- Regulatory pathway (IND, NDA, BLA, 510(k), PMA)
- Alignment with FDA, EMA, and global authorities
- History of regulatory interactions
- Potential approval risks and timelines
Key Questions
- Is the regulatory pathway clear and achievable?
- What are the risks of delay or rejection?
- Are expedited pathways available?
Value
- Reduces regulatory uncertainty
- Improves timeline forecasting
- Identifies critical inflection points
5. CMC & Manufacturing Assessment
What We Assess
- Process development and scalability
- Manufacturing readiness and robustness
- CDMO strategy and supply chain risks
- Product quality and consistency
Key Questions
- Can the product be manufactured at scale?
- Are there risks in tech transfer or supply chain?
- Is CMC a potential bottleneck?
Value
- Prevents investment in non-scalable products
- Identifies hidden operational risks
- Supports realistic commercialization planning
6. Quality & Compliance
What We Assess
- GMP quality systems and compliance
- Inspection readiness and audit history
- CAPA and remediation programs
- Regulatory compliance culture
Key Questions
- Is the organization inspection-ready?
- Are there compliance risks that could delay progress?
- Is quality aligned with regulatory expectations?
Value
- Reduces risk of regulatory actions
- Protects investment from compliance failures
- Strengthens operational confidence
7. Commercial & Market Assessment
What We Assess
- Market size and growth potential
- Competitive landscape and positioning
- Pricing and reimbursement dynamics
- Adoption drivers and barriers
Key Questions
- Is there a viable and scalable market?
- How differentiated is the product?
- What is the revenue potential?
Value
- Validates commercial opportunity
- Supports valuation assumptions
- Identifies go-to-market risks
8. Management & Operational Capability
What We Assess
- Leadership team experience and track record
- Organizational structure and execution capability
- Operational readiness for scale
- Gaps in leadership or expertise
Key Questions
- Can this team execute the plan?
- Are there critical capability gaps?
- Is additional leadership required?
Value
- Assesses execution risk
- Identifies needs for operational support
- Supports post-investment strategy
9. Transaction & Deal Support
What We Provide
- Integrated diligence reports
- Risk-adjusted valuation insights
- Red flag identification and mitigation strategies
- Support for investment committee discussions
Value
- Enables faster, more confident decisions
- Strengthens negotiation positioning
- Improves investment outcomes
Deliverables
- Executive summary with key risks and opportunities
- Detailed technical diligence report
- Risk matrix with mitigation strategies
- Development timeline and milestone assessment
- Go / No-Go recommendation framework
Who We Work With
- Venture capital firms (early- and growth-stage)
- Private equity firms (platform and roll-up strategies)
- Family offices and strategic investors
- Corporate venture and business development teams
When We Are Engaged
- Pre-investment diligence
- Late-stage deal validation
- Portfolio company assessment
- In-licensing and acquisition evaluation
- Post-investment value creation
What Differentiates Our Platform
- Operator-Led Insight
- Full Lifecycle Coverage
- Independent Perspective
- Speed & Precision
Value to Investors
- Reduce Investment Risk
- Improve Deal Quality
- Strengthen Negotiation
- Drive Portfolio Value
Bottom Line
We provide the scientific, clinical, and operational insight investors need to make confident, high-quality life sciences investment decisions—reducing risk and maximizing return potential.
Number of companies: 2
Number of contacts: 2
Back to Home
